<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3853">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04631705</url>
  </required_header>
  <id_info>
    <org_study_id>Uni-Koeln-4370</org_study_id>
    <nct_id>NCT04631705</nct_id>
  </id_info>
  <brief_title>SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation</brief_title>
  <official_title>A Phase 1/2a Trial of the Inhaled Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZKS KÃ¶ln</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first-in-human phase 1/2a trial of the inhaled administration of the&#xD;
      SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c in healthy volunteers and&#xD;
      SARS-CoV-2-infected individuals. It will evaluate the safety, pharmacokinetic profile,&#xD;
      immunogenicity, and antiviral activity of DZIF-10c.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The phase 1 component of this trial consists of a single-inhalation open-label&#xD;
      dose-escalation phase (Groups 1A-1C and Groups 2A-2C). Subsequently, the highest tolerated&#xD;
      dose tested will be administered to an expansion cohort of SARS-CoV-2-infected individuals&#xD;
      (Group 2D). In this randomized and blinded group, participants will receive DZIF-10c or&#xD;
      placebo both by inhalation and intravenous infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This study consists of an open-label dose escalation phase in both healthy volunteers (Groups 1A-1C) and SARS-CoV-2-infected participants (Groups 2A-2C).&#xD;
After completion of the dose escalation phase, SARS-CoV-2-infected individuals will be enrolled into a randomized placebo-controlled expansion cohort (Group 2D).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Adverse Events after a single DZIF-10c inhalation [Safety and Tolerability]</measure>
    <time_frame>3 months</time_frame>
    <description>Primary target variables are (S)AEs and Adverse Events of Special Interest (AESIs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Adverse Events after a single combined DZIF-10c inhalation and infusion [Safety and Tolerability]</measure>
    <time_frame>3 months</time_frame>
    <description>Primary target variables are (S)AEs and Adverse Events of Special Interest (AESIs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter AUC0-672</measure>
    <time_frame>0 to 672 hours</time_frame>
    <description>AUC0-672 (the area under the concentration-time curve of DZIF-10c in serum over the time interval from 0 to 672 hours (Day 28)) after inhaled and combined inhaled and intravenous application</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of anti-drug antibodies</measure>
    <time_frame>3 months</time_frame>
    <description>Frequency of the development of anti-drug antibodies targeting DZIF-10c determined by immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of anti-drug antibodies</measure>
    <time_frame>3 months</time_frame>
    <description>Titer of anti-drug antibodies targeting DZIF-10c determined by immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in viral load in nasopharyngeal swabs after DZIF-10c administration</measure>
    <time_frame>28 days</time_frame>
    <description>Change in SARS-CoV-2 RNA from baseline in nasopharyngeal swabs as determined by qRT-pCR</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Group 1A (uninfected) - low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SARS-CoV-2-uninfected volunteers will receive a single dose of DZIF-10c by inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1B (uninfected) - mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SARS-CoV-2-uninfected volunteers will receive a single dose of DZIF-10c by inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1C (uninfected) - high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SARS-CoV-2-uninfected volunteers will receive a single dose of DZIF-10c by inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2A (infected) - low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SARS-CoV-2-infected volunteers will receive a single dose of DZIF-10c by inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2B (infected) - mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SARS-CoV-2-infected volunteers will receive a single dose of DZIF-10c by inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2C (infected) - high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SARS-CoV-2-infected volunteers will receive a single dose of DZIF-10c by inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2D (infected)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SARS-CoV-2-infected volunteers will be randomized 1:1:1 to receive DZIF-10c by inhalation and infusion, DZIF-10c by inhalation and placebo by infusion, or placebo by inhalation and infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DZIF-10c</intervention_name>
    <description>Inhaled administration of the human monoclonal antibody DZIF-10c</description>
    <arm_group_label>Group 1A (uninfected) - low dose</arm_group_label>
    <arm_group_label>Group 1B (uninfected) - mid dose</arm_group_label>
    <arm_group_label>Group 1C (uninfected) - high dose</arm_group_label>
    <arm_group_label>Group 2A (infected) - low dose</arm_group_label>
    <arm_group_label>Group 2B (infected) - mid dose</arm_group_label>
    <arm_group_label>Group 2C (infected) - high dose</arm_group_label>
    <arm_group_label>Group 2D (infected)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DZIF-10c</intervention_name>
    <description>Intravenous administration of the human monoclonal antibody DZIF-10c</description>
    <arm_group_label>Group 2D (infected)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhalation of DZIF-10c diluent as placebo</description>
    <arm_group_label>Group 2D (infected)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo</description>
    <arm_group_label>Group 2D (infected)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Groups 1A-1C&#xD;
&#xD;
          -  Age 18-65.&#xD;
&#xD;
          -  SARS-CoV-2-RNA negative naso- or oropharyngeal swab obtained within 3 calendar days&#xD;
             before study drug administration by NAAT (e.g., qRT-PCR).&#xD;
&#xD;
          -  Non-reactivity of serum antibodies (IgG; and IgA and/or IgM when tested) against&#xD;
             SARS-CoV-2 by serological assay at screening.&#xD;
&#xD;
        Groups 2A-2D&#xD;
&#xD;
          -  Age 18-70.&#xD;
&#xD;
          -  SARS-CoV-2-RNA positive naso- or oropharyngeal swab obtained within 3 calendar days&#xD;
             before study drug administration by NAAT (e.g., qRT-PCR).&#xD;
&#xD;
          -  Onset of COVID-19 symptoms (e.g., sore throat, cough, fever, chills, fatigue, dys- or&#xD;
             anosmia, dys- or ageusia, headache, muscle pain, gastrointestinal symptoms) within 7&#xD;
             days prior to study drug administration or Non-reactivity of serum or plasma&#xD;
             antibodies (IgG; and IgA and/or IgM when tested) against SARS-CoV-2 by serological&#xD;
             assay at screening.&#xD;
&#xD;
          -  Disease severity score 1-4 as defined by the WHO Clinical Progression Scale (WHO,&#xD;
             Lancet Inf Dis 2020)&#xD;
&#xD;
        Exclusion Criteria (all groups):&#xD;
&#xD;
          -  Known hypersensitivity to any constituent of the investigational medicinal product.&#xD;
&#xD;
          -  Hepatitis B infection indicated by detectable HBsAg (Hepatitis B surface antigen) in&#xD;
             blood.&#xD;
&#xD;
          -  Detectable antibodies against hepatitis C virus in blood unless active hepatitis C is&#xD;
             ruled out by negative HCV-RNA.&#xD;
&#xD;
          -  HIV infection indicated by detectable HIV antigen and/or HIV antibodies in blood.&#xD;
&#xD;
          -  Neutrophil count â¤1,000 cells/Âµl&#xD;
&#xD;
          -  Hemoglobin â¤10 g/dl&#xD;
&#xD;
          -  Platelet count â¤100,000 cells/Âµl&#xD;
&#xD;
          -  ALT â¥2.0 x ULN&#xD;
&#xD;
          -  AST â¥2.0 x ULN&#xD;
&#xD;
          -  Total bilirubin â¥1.5 ULN&#xD;
&#xD;
          -  eGFR &lt;60 ml/min/1.73m2&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Any vaccination within 14 days prior to DZIF-10c administration.&#xD;
&#xD;
          -  Receipt of any SARS-CoV-2 vaccine or SARS-CoV-2 monoclonal antibody in the past.&#xD;
&#xD;
          -  Diagnosis of bronchial asthma or history of bronchial hyperresponsiveness, COPD,&#xD;
             pulmonary fibrosis, or other chronic lung diseases.&#xD;
&#xD;
          -  Any chronic or clinically significant medical condition that in the opinion of&#xD;
             investigator would jeopardize the safety or rights of the volunteer.&#xD;
&#xD;
          -  History of systemic corticosteroids, immunosuppressive anti-cancer, or other&#xD;
             medications considered significant by the trial physician within the last 6 months (a&#xD;
             single administration of systemic corticosteroids within â¤6 months and â¥4 weeks of&#xD;
             enrollment is acceptable).&#xD;
&#xD;
          -  Participation in another clinical trial of an investigational medicinal product within&#xD;
             the past 12 weeks or expected participation during this study.&#xD;
&#xD;
          -  Dependency on the principal investigator or study staff; or site personnel directly&#xD;
             affiliated with this trial.&#xD;
&#xD;
          -  Legally incapacitated individuals&#xD;
&#xD;
          -  Individuals held in an institution by legal or official order&#xD;
&#xD;
          -  If engaging in sexual activity that could result in pregnancy, inability or&#xD;
             unwillingness to comply with the requirements for highly effective contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerd FÃ¤tkenheuer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cologne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henning Gruell, MD</last_name>
    <phone>+49-221-478-96973</phone>
    <email>henning.gruell@uk-koeln.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florian Klein, MD</last_name>
    <phone>+49-221-478-85801</phone>
    <email>florian.klein@uk-koeln.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Cologne</name>
      <address>
        <city>Cologne</city>
        <state>NRW</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerd FÃ¤tkenheuer, MD</last_name>
      <phone>+49-221-478-38374</phone>
      <email>gerd.faetkenheuer@uk-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Jakob Malin, MD</last_name>
      <phone>+49-221-478-38374</phone>
      <email>jakob.malin@uk-koeln.de</email>
    </contact_backup>
    <investigator>
      <last_name>Gerd FÃ¤tkenheuer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jakob Malin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Kreer C, Zehner M, Weber T, Ercanoglu MS, Gieselmann L, Rohde C, Halwe S, Korenkov M, Schommers P, Vanshylla K, Di Cristanziano V, Janicki H, Brinker R, Ashurov A, KrÃ¤hling V, Kupke A, Cohen-Dvashi H, Koch M, Eckert JM, Lederer S, Pfeifer N, Wolf T, Vehreschild MJGT, Wendtner C, Diskin R, Gruell H, Becker S, Klein F. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell. 2020 Sep 17;182(6):1663-1673. doi: 10.1016/j.cell.2020.08.046.</citation>
    <PMID>32946786</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Florian Klein</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Covid-19</keyword>
  <keyword>Monoclonal Antibody</keyword>
  <keyword>Inhalation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

